Premium
[P4–118]: HIGH‐DENSITY LIPOPROTEINS SUPPRESS Aβ‐INDUCED BRAIN MICROVASCULAR ENDOTHELIAL CELL ACTIVATION
Author(s) -
Button Emily B.,
Robert Jerome,
Stukas Sophie,
Boyce Guilaine,
Gibbs Ebrima,
Cowan Catherine,
Cheng Wai Hang,
Soo Sonja,
Yuen Brian,
Bahrabadi Arvin,
Kang Kevin,
Kulic Iva,
Francis Gordon,
Cashman Neil R.,
Wellington Cheryl
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1984
Subject(s) - scavenger receptor , endothelial stem cell , umbilical vein , cell adhesion molecule , endothelium , chemistry , microbiology and biotechnology , inflammation , stimulation , tumor necrosis factor alpha , blood–brain barrier , in vitro , lipoprotein , cholesterol , endocrinology , medicine , biology , biochemistry , central nervous system
Background:Vascular endothelial growth factor (VEGF) is an angioneurin involved in the regulation of vascular and neural functions relevant for the pathophysiology of Alzheimer’s disease (AD), but the influence of AD severity and ApoE4 status on circulating VEGF and its relationship with cognition have not been investigated. Methods: Serum VEGF levels and cognitive performance were evaluated in AD, amnestic mild cognitive impairment (MCI) and control subjects. VEGF levels were measured in baseline serum samples by using specific ELISA kits for VEGF.Results:VEGF levelswere higher inAD patients than in MCI cases and controls (p<0.05), and showed a progressive increase with clinical severity in the whole study population (p<0.01). Among AD patients, severity-related VEGF elevations were significant in ApoE4 carriers (p<0.05), but not in non-carriers. Increased VEGF levels were associated with disease severity, and showed mild correlations with cognitive impairment that were only consistent for the ADAS-cog+ items remembering test instructions (memory) and maze task (executive functions) in the group of AD patients (p<0.05).On the other hand, higherVEGFvalueswere related to better memory and language performance in ApoE4 carriers with moderately-severe AD. Conclusions:VEGF serum levels are elevated and correlatewith cognitive impairment in AD patients; show a significant severity-related increase in ApoE4 carriers; and are associated to better memory and language performance in moderately-severe ApoE4cases.Thesefindings are pointing toVEGFas a relevantmolecular target in AD pathology and therapy; and suggest that increases in VEGF levels might represent an endogenous response driven by pathological factors and could entail cognitive benefits, particularly in AD ApoE4 carriers.